Zenodo
Is SGLT2 inhibitor therapy recommended for patients with diabetes and chronic kidney disease classified as G3aA1?
By Tripdatabase.
Abstract
Evidence shows that SGLT2 inhibitors are recommended for patients with diabetes and CKD classified as G3aA1, due to their significant benefits in improving renal and cardiovascular outcomes.
Keywords
- Diabetes Treatment and Management
- SGLT2 inhibitors
- type 2 diabetes
- chronic kidney disease
- renal outcomes
- cardiovascular outcomes
- treatment guidelines
- Open access